← Back to Search

Monoclonal Antibodies

Belimumab for Rheumatoid Arthritis

Phase 2
Waitlist Available
Research Sponsored by Human Genome Sciences Inc.
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up up to 5 years
Awards & highlights
No Placebo-Only Group
All Individual Drugs Already Approved

Summary

This is a continuation trial of LymphoStat-B™ to evaluate the long-term safety in subjects with Rheumatoid Arthritis that completed study LBRA01 and benefitted from treatment.

Eligible Conditions
  • Rheumatoid Arthritis

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~up to 5 years
This trial's timeline: 3 weeks for screening, Varies for treatment, and up to 5 years for reporting.

Treatment Details

Study Objectives

Study objectives can provide a clearer picture of what you can expect from a treatment.
Primary study objectives
To Evaluate the Long-term Safety of LymphoStat-B™ in Subjects With RA.
Secondary study objectives
The Efficacy Endpoints Will Include Long-term ACR Responses, DAS28 Response, C-reactive Protein (CRP), Erythrocyte Sedimentation Rate (ESR), and Rheumatoid Factor (RF).

Side effects data

From 2016 Phase 3 trial • 738 Patients • NCT00712933
28%
Headache
21%
Nasopharyngitis
19%
Diarrhoea
18%
Arthralgia
18%
Influenza
16%
Cough
14%
Back pain
12%
Urinary tract infection bacterial
11%
Viral upper respiratory tract infection
11%
Upper respiratory tract infection
10%
Pyrexia
9%
Urinary tract infection
9%
Hypertension
9%
Myalgia
9%
Nausea
8%
Abdominal pain upper
8%
Rash
8%
Abdominal pain
8%
Dizziness
8%
Fatigue
7%
Herpes zoster
7%
Insomnia
7%
Upper respiratory tract infection bacterial
7%
Gastritis
7%
Vomiting
7%
Depression
7%
Gastroenteritis
7%
Alopecia
7%
Bronchitis bacterial
7%
Pain in extremity
6%
Oedema peripheral
6%
Bronchitis
6%
Anaemia
6%
Oral herpes
6%
Pruritus
5%
Dyspepsia
5%
Hypotension
5%
Pharyngitis bacterial
5%
Non-cardiac chest pain
5%
Rhinitis allergic
2%
Cellulitis
2%
Lupus nephritis
2%
Pneumonia bacterial
1%
Leukopenia
1%
Pneumonia
1%
Thrombocytopenia
1%
Osteonecrosis
1%
Raynaud's phenomenon
1%
Lupus vasculitis
1%
Appendicitis
1%
Cholelithiasis
100%
80%
60%
40%
20%
0%
Study treatment Arm
Belimumab 10mg/kg IV

Awards & Highlights

No Placebo-Only Group
All patients enrolled in this study will receive some form of active treatment.
All Individual Drugs Already Approved
Therapies where all constituent drugs have already been approved are likely to have better-understood side effect profiles.

Trial Design

1Treatment groups
Experimental Treatment
Group I: BelimumabExperimental Treatment1 Intervention
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
Belimumab
FDA approved

Find a Location

Who is running the clinical trial?

Human Genome Sciences Inc.Lead Sponsor
32 Previous Clinical Trials
8,820 Total Patients Enrolled
GSK Clinical TrialsStudy DirectorGlaxoSmithKline
3,602 Previous Clinical Trials
6,144,475 Total Patients Enrolled
1 Trials studying Rheumatoid Arthritis
~7 spots leftby Oct 2025
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top